Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036121 · ClinicalTrials.gov registry record · Phase 1
A Study of ADRX-0706 in Select Advanced Solid Tumors
A Phase 1 study of Cervical Cancer and Solid Tumors, sponsored by Adcentrx Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT06036121: Active Phase 1 study of Cervical Cancer and Solid Tumors, sponsored by Adcentrx Therapeutics.
NCT06036121 is a Phase 1 study of Cervical Cancer and Solid Tumors that is active but no longer recruiting, run by Adcentrx Therapeutics. The registered enrollment target is 144 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06036121, a Phase 1 study of Cervical Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Adcentrx Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Conditions Studied
Interventions
- DRUG ADRX-0706
Study Locations (20)
Other
- Beijing University Third Hospital - Beijing
- Fujian Cancer Hospital - Fujian
- Sun Yat-sen University Cancer Center - Guangzhou
- Hunan Cancer hospital - Hunan
- Shandong Cancer Hospital - Jinan
- Shanghai East Hospital - Shanghai
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Cancer - Detroit
- START Midwest - Grand Rapids
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- UCLA - Los Angeles
Florida
- Comprehensive Hematology Oncology - St. Petersburg
- Moffitt Cancer Center - Tampa
Texas
- University of Texas MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
Ohio
- The Ohio State University Wexner Medical Center - Hilliard
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Tennessee
- Sarah Cannon Cancer Network - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT06036121 still lists
NCT06036121 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (75% lower).
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADRX-0706 is the first listed.
NCT06036121 names 20 study sites across 9 states, led by Other, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT06036121 about?
NCT06036121 is a clinical study titled "A Study of ADRX-0706 in Select Advanced Solid Tumors". The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
What is the current status of trial NCT06036121?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2023-09-26. Estimated completion is 2026-12.
What conditions does trial NCT06036121 study?
This clinical trial studies the following conditions: Cervical Cancer, Solid Tumors, Urothelial Cancer, Triple Negative Breast Cancer (TNBC).
What interventions are being tested in trial NCT06036121?
The interventions under investigation include: ADRX-0706 (DRUG).
Who is sponsoring clinical trial NCT06036121?
This trial is sponsored by Adcentrx Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06036121 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06036121's enrollment target sits among peer trials
144 56th of 144 higher than 89 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI